BDSX vs. PSNL, VMD, DCGO, LFMD, CORBF, SERA, AIRS, TOI, QIPT, and EUDA
Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include Personalis (PSNL), Viemed Healthcare (VMD), DocGo (DCGO), LifeMD (LFMD), Global Cord Blood (CORBF), Sera Prognostics (SERA), AirSculpt Technologies (AIRS), Oncology Institute (TOI), Quipt Home Medical (QIPT), and EUDA Health (EUDA). These companies are all part of the "healthcare" industry.
Biodesix vs.
Biodesix (NASDAQ:BDSX) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, community ranking, media sentiment and valuation.
Biodesix has a net margin of -66.84% compared to Personalis' net margin of -104.52%. Personalis' return on equity of -66.07% beat Biodesix's return on equity.
Personalis received 95 more outperform votes than Biodesix when rated by MarketBeat users. However, 75.00% of users gave Biodesix an outperform vote while only 68.31% of users gave Personalis an outperform vote.
Biodesix presently has a consensus price target of $2.95, indicating a potential upside of 437.34%. Personalis has a consensus price target of $7.80, indicating a potential upside of 144.51%. Given Biodesix's higher probable upside, research analysts plainly believe Biodesix is more favorable than Personalis.
Biodesix has higher earnings, but lower revenue than Personalis. Personalis is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.
21.0% of Biodesix shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 69.2% of Biodesix shares are held by company insiders. Comparatively, 3.8% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Biodesix has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.
In the previous week, Personalis had 1 more articles in the media than Biodesix. MarketBeat recorded 1 mentions for Personalis and 0 mentions for Biodesix. Biodesix's average media sentiment score of 0.00 equaled Personalis'average media sentiment score.
Summary
Personalis beats Biodesix on 8 of the 15 factors compared between the two stocks.
Get Biodesix News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodesix Competitors List
Related Companies and Tools
This page (NASDAQ:BDSX) was last updated on 4/18/2025 by MarketBeat.com Staff
Buy BDSX Stock Free BDSX Stock Alerts